VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | The impact of bortezomib dose adjustment in the OPTIMISMM study

Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the impact of bortezomib dose adjustment in the OPTIMISMM trial (NCT01734928), testing the safety and efficacy of pomalidomide, bortezomib and low-dose dexamethasone in subjects with relapsed/refractory (R/R) multiple myeloma. The trial showed that adjusting bortezomib dose does not result in a loss of efficacy with the three-drug combination. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter